<DOC>
	<DOC>NCT01965652</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.</brief_summary>
	<brief_title>Long Term Safety of Naldemedine</brief_title>
	<detailed_description>This is a Phase 3, multi-center, randomized double-blind, placebo controlled, parallel-group study designed to evaluate the long term safety of naldemedine compared to placebo for the treatment of opioid-induced constipation (OIC) in subjects with non-malignant chronic pain receiving opioid therapy.</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Inclusion Criteria 1. Subjects aged 18 to 80 years inclusive at the time of informed consent 2. Subjects must have nonmalignant chronic pain treated and must have opioid induced constipation (OIC) 3. Subjects must be treated with a stable opioid regimen at a total daily dose on average of â‰¥ 30 mg equivalents of oral morphine sulfate 4. Subjects may or may not be on a routine laxative regimen at the time of Screening Exclusion Criteria 1. Evidence of significant structural abnormalities of the gastrointestinal (GI) tract 2. Evidence of active medical diseases affecting bowel transit 3. History of pelvic disorders that may be a cause of constipation 4. Surgery (except for minor procedures) within 60 days of Screening 5. History of chronic constipation prior to starting analgesic medication or any potential nonopioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g. mechanical GI obstruction) 6. Subjects who have never taken laxatives for the treatment of OIC 7. Current use of any prohibited medication including opioid antagonists, partial or mixed agonists/antagonists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Opioid Induced Constipation</keyword>
</DOC>